Article
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Leukemia - 1 Apr 2015
Inoue D, Kitaura J, Matsui H, Hou H-A, Chou W-C, Nagamachi A, Kawabata K C, Togami K, Nagase R, Horikawa S, Saika M, Micol J-B, Hayashi Y, Harada Y, Harada H, Inaba T, Tien H-F, Abdel-Wahab O, Kitamura T
Abstract excerpt
Mutations in ASXL1 are frequent in patients with myelodysplastic syndrome (MDS) and are associated with adverse survival, yet the molecular pathogenesis of ASXL1 mutations (ASXL1-MT) is not fully understood. Recently, it has been found that deletion of Asxl1 or expression of C-terminal-truncating ASXL1-MTs inhibit myeloid differentiation and induce MDS-like disease in mice. Here, we find that SET-binding protein...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.